• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

AbbVie Inc. (NYSE: ABBV)

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie employs more than 26,000 people worldwide and markets medicines in more than 170 countries. *

 

	Start	2013-01-01 splitoff
	Group	AbbVie (Group)
	Predecessor	Abbott Laboratories Inc. (NYSE: ABT)
	Industry	pharmaceutical
	Region	Chicago, IL
	Country	United States (USA)
	Street	1 N Waukegan Rd
	City	60064 North Chicago, IL
		Address record changed: 2019-09-11
Basic data	Employees	H: 10,001 to 50,00 (2015-03-30)
	Currency	USD
	Annual sales	32,753,000,000 (revenues, net, consolidated (2018) 2018-12-31)
	Profit	5,687,000,000 (2018-12-31)
		* Document for �About Section�: BioMed X GmbH. (3/30/15). "Press Release: AbbVie and BioMed X Collaborate to Develop Novel Approaches for the Treatment of Alzheimer's Disease". Heidelberg.
		Record changed: 2019-11-09

Advertisement

More documents for AbbVie (Group)

• [1] Disc Medicine. (10/29/19). "Press Release: Disc Medicine Expands Pipeline Focused on Hepcidin Pathway. Enters into Exclusive Agreement with AbbVie for Series of Hemojuvelin Antagonist Monoclonal Antibodies". Cambridge, MA....
• [2] AbbVie Inc.. (6/25/19). "Press Release: AbbVie to Acquire Allergan in Transformative Move for Both Companies"....
• [3] Zelluna Immunotherapy AS. (6/25/19). "Press Release: Zelluna Immunotherapy Appoints Jens-Peter Marschner as Chief Medical Officer". Oslo....
• [4] Huntsworth plc. (5/30/19). "Press Release: Huntsworth plc Appoints Annabelle Sandeman as Its New Global Head of Commercial Strategy". London....
• [5] Mission Therapeutics Ltd.. (5/1/19). "Press Release: Dr. James Summers Appointed to Mission Therapeutics’ Board of Directors". Cambridge....
• [6] Argenx SE. (3/14/19). "Press Release: Argenx to Receive First Clinical Milestone Payment for Product Candidate Developed". Breda & Ghent....
• [7] New York Times [The Editorial Board]. (2/24/19). "News: It’s Time for Pharmaceutical Companies to Have Their Tobacco Moment"....
• [8] ADC Therapeutics S.A.. (2/20/19). "Press Release: ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma"...
• [9] AbbVie Inc.. (1/25/19). "Press Release: AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results". North Chicago, IL....
• [10] Carroll, John [Endpoints]. (12/28/18). "News: Backed by a Pioneer in BiTE Tech, Harpoon Marks a Course for an IPO and an Early Display of Potential"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.